Success Stories: EB-1A Approved for Clinical Cytogeneticist in Wisconsin in the Field of Human Genetics
On April 2, 2015, We Received Another EB1-A (Alien of Extraordinary Ability) Approval for a Clinical Cytogeneticist in the Field of Human Genetics (Approval Notice)
Position at the Time of Case Filing: Clinical Cytogeneticist
Country of Origin: India
Service Center: Nebraska Service Center (NSC)
State of Residence at the Time of Filing: Wisconsin
Approval Notice Date: April 2, 2015
Processing Time: 15 Days (Premium Processing Requested)
In this case, the client that we had the opportunity to work with was a Clinical Cytogeneticist from India in the field of Human Genetics. He had conducted his research in the highly specialized area of clinical cytogenetics has allowed his research to be particularly original, with applications such as the development of a novel chromosomal microarray (CMA) test, which scans the entire genome in order to detect subtle malformations corresponding to the appearance of autism spectrum disorders, intellectual disability, and other neurological disorders. His work had resulted in 11 peer-reviewed scientific articles and numerous presentations at national and international conferences. At the time that his case was filed, his publications had been cited at least 169 times by independent and leading researchers from prestigious institutions and organizations around the world, indicating the major significance of his work. He had also reviewed 5 manuscripts for distinctive, internationally-circulated journals. His superior level of expertise was confirmed in the following quote from an independent recommender, “His research touches on an important subject within the American medical field. With his continued research the scientific community will continue to make major advances toward understanding autism.” It was our goal to prove that our client qualified for classification as an Alien of Extraordinary Ability given that he sought to remain in the United States to continue work in the area of Human Genetics, and that his continued research would substantially and prospectively benefit the United States. With the proof and documentation that we provided, his case was approved in 15 days.